Evogene Reports Second Quarter 2025 Financial Results
1. Evogene reported strong revenue growth, reaching $3.2 million in H1 2025. 2. Cost reduction plans led to a significant decrease in operating expenses. 3. Strategic focus shifts to ChemPass AI for pharmaceuticals and agriculture. 4. Evogene's cash position strengthened after selling Lavie Bio for $18.71 million. 5. Workforce reductions aim to improve operational efficiency and streamline operations.